ADDED
Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant s fiscal year ended December 31, 2025.
In particular, the following considerations, among others, may offset our competitive strengths, or have a negative effect on our business strategy, which could cause a decline in the price of shares of our Common Stock or Warrants and result in a loss of all or a portion of your investment: Risks Related to Our Financial Condition and Capital Requirements We are a clinical-stage biotechnology company with a limited operating history and a history of significant net losses.
We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.
We will need substantial additional funding to advance our product candidates and support our operations.
As of December 31, 2025, we had approximately $1.4 million in cash and cash equivalents.
Our recurring losses and need for additional financing raise substantial doubt about our ability to continue as a going concern.
If we are unable to obtain sufficient funding, we may be forced to delay, reduce, or eliminate our product development programs or liquidate our assets.
Risks Related to the Development and Commercialization of Our Product Candidates Our success depends heavily on the successful clinical development and regulatory approval of our lead product candidate, EB103, and our ability to expand our pipeline using the ARTEMIS platform.
Clinical trials are expensive, time-consuming, difficult to design, and involve uncertain outcomes.
We may experience delays in enrolling patients, serious adverse events (such as those observed in similar therapies), or failures to demonstrate safety and efficacy, which could prevent regulatory approval.
REMOVED
In particular, the following considerations, among others, may offset our competitive strengths, or have a negative effect on our business strategy, which could cause a decline in the price of shares of our Common Stock or Warrants and result in a loss of all or a portion of your investment: We are a clinical stage biotechnology company and expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.
Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations.
Our current or potential future product candidates may not demonstrate the safety, purity, or efficacy necessary to become approvable or commercially viable.
Although we intend to explore other therapeutic opportunities in addition to the product candidates we are currently pursuing, we may fail to identify viable new product candidates for clinical development, which could materially harm our business.
Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
We rely on third parties to conduct our preclinical studies, and plan to rely on third parties to conduct clinical trials, and those third parties may not perform satisfactorily.
If third parties on which we intend to rely to conduct certain preclinical and clinical studies do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed or unsuccessful, and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected, or at all.
We may not be able to maintain our existing strategic partnerships and collaboration arrangements or enter into new strategic partnerships and collaborations for the development, manufacturing, and commercialization of product candidates on terms that are acceptable to us, or at all.
If Eureka, or other third parties, encounter difficulties in production, our ability to supply our product candidates for clinical trials or, if approved, for commercial sale, could be delayed or halted entirely.
We face competition from companies that have developed or may develop product candidates for the treatment of the diseases that we may target, including companies developing novel therapies and platform technologies.